Analysts fell to the sidelines weighing in on Redfin (RDFN – Research Report) and Sabra Healthcare REIT (SBRA – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
In a report released yesterday, Scott Devitt from Stifel Nicolaus reiterated a Hold rating on Redfin, with a price target of $15.00. The company’s shares closed last Thursday at $11.33, close to its 52-week low of $10.94.
According to TipRanks.com, Devitt is a 5-star analyst with an average return of
Currently, the analyst consensus on Redfin is a Hold with an average price target of $24.94, which is a 99.0% upside from current levels. In a report issued on April 25, Jefferies also maintained a Hold rating on the stock with a $13.00 price target.
Sabra Healthcare REIT (SBRA)
Mizuho Securities analyst Vikram Malhorta maintained a Hold rating on Sabra Healthcare REIT on May 4 and set a price target of $16.00. The company’s shares closed last Thursday at $13.53.
According to TipRanks.com, Malhorta is a 3-star analyst with an average return of
Currently, the analyst consensus on Sabra Healthcare REIT is a Moderate Buy with an average price target of $15.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RDFN: